Asthma and lower airway diseaseMetabolomic profiling of asthma and chronic obstructive pulmonary disease: A pilot study differentiating diseases
Section snippets
Methods
For details, see the Methods section in this article's Online Repository et al.10, 11
Baseline patients' characteristics for the metabolomic model of asthma versus COPD
The populations with COPD were both significantly older than the asthma groups, although the asthma group from McMaster was significantly older than the other asthma cohorts in Edmonton. The sex difference among these groups was similar. Subjects having an asthma exacerbation at the University of Alberta were not excluded if they currently smoked; however, the number of pack years of smoking was much lower in the asthma group compared with the COPD exacerbation group (a median of 5 compared
Discussion
We have provided proof-of-concept evidence that urine metabolites can be used to differentiate asthma from COPD. We have the metabolomic data comparing asthma and COPD before and after exacerbation, but the focus of this report was on the differentiation of asthma from COPD. A subsequent article will compare metabolites for exacerbation.
COPD and asthma involve a number of unique cellular pathways, but these pathways can still converge to produce a similar clinical outcome. Symptoms or lung
References (59)
- et al.
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial
Lancet
(2002) - et al.
Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPD-asthma
Chest
(2014) - et al.
Inflammation in COPD: implications for management
Am J Med
(2012) - et al.
Urinary bromotyrosine measures asthma control and predicts asthma exacerbations in children
J Pediatr
(2011) - et al.
Biomarker-based asthma phenotypes of corticosteroid response
J Allergy Clin Immunol
(2015) - et al.
Characterization of reactive nitrogen species in allergic asthma
Ann Allergy Asthma Immunol
(2014) - et al.
Role of the L-citrulline/L-arginine cycle in iNANC nerve-mediated nitric oxide production and airway smooth muscle relaxation in allergic asthma
Eur J Pharmacol
(2006) Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor
J Nutr
(2004)- et al.
The metabolic fate of branched-chain amino acids and 2-oxo acids in rat muscle homogenates and diaphragms
Int J Biochem
(1985) - et al.
Increased urinary excretion of 3-hydroxyisovaleric acid and decreased urinary excretion of biotin are sensitive early indicators of decreased biotin status in experimental biotin deficiency
Am J Clin Nutr
(1997)
The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism
Clin Biochem
Diet and asthma: vitamins and methyl donors
Lancet Respir Med
Asthma, allergy, and responses to methyl donor supplements and nutrients
J Allergy Clin Immunol
Urinary N-methylhistamine in asthmatic children receiving azelastine hydrochloride
Ann Allergy Asthma Immunol
Determination of N-methylhistamine in urine as an indicator of histamine release in immediate allergic reactions
J Allergy Clin Immunol
The progression of comorbidity in IL-18 transgenic chronic obstructive pulmonary disease mice model
Biochem Biophys Res Commun
Nicotinamide, a missing link in the early stress response in eukaryotic cells: a hypothesis with special reference to oxidative stress in plants
FEBS Lett
Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations
Eur Respir J
Biomarkers predicting response to corticosteroid therapy in asthma
Treat Respir Med
Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways
Curr Opin Drug Discov Devel
Metabolomics-based methods for early disease diagnostics
Expert Rev Mol Diagn
Nuclear magnetic resonance spectroscopic and principal components analysis investigations into biochemical effects of three model hepatotoxins
Chem Res Toxicol
Exploring human metabolites using the human metabolome database
Curr Protoc Bioinformatics
Metabolomic biomarkers in a model of asthma exacerbation: urine nuclear magnetic resonance
Am J Respir Crit Care Med
Metabolomic profiling of asthma: diagnostic utility of urine nuclear magnetic resonance spectroscopy
J Allergy Clin Immunol
Assessment of eosinophil granule proteins in various body fluids: is there a relation to clinical variables in childhood asthma?
Clin Exp Allergy
Urinary excretion of leukotriene E4 and eosinophil protein X in children with atopic asthma
Eur Respir J
The clinical significance of exhaled nitric oxide in asthma
Can Respir J
Update on clinical inflammometry for the management of airway diseases
Can Respir J
Cited by (71)
Metabolomics in COPD
2023, Archivos de BronconeumologiaAllergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions: Similarities, differences, and misconceptions
2022, Annals of Allergy, Asthma and ImmunologyCitation Excerpt :The identification of FeNO suggests that biological samples other than blood could be considered for biomarker identification, and other methodological approaches too. Initial and proof-of-concept studies suggest that metabolic profiling may identify disease signatures across respiratory diseases and in patients with food allergies.65,68,69 Although this concept is emerging in the asthma field, an extension of this application could be considered for identifying potential biomarkers for biologic treatment response.
High-coverage lipidomics analysis reveals biomarkers for diagnosis of acute exacerbation of chronic obstructive pulmonary disease
2022, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesPrediction of sublingual immunotherapy efficacy in allergic rhinitis by serum metabolomics analysis
2021, International ImmunopharmacologyMetabolic profiling of organic and fatty acids in chronic and autoimmune diseases
2021, Advances in Clinical ChemistryCitation Excerpt :The use of a validated model to predict asthma exacerbations based on identified metabolites could be crucial for efficient treatment and control of different clinical cases of asthma. The metabolomic analysis of COPD patients with different pathogenic background has revealed metabolic dysregulation appointing as potential biomarkers for the disease metabolites involved in amino acid, lipid and energy metabolism, as well as oxidative stress [58–61]. Specifically, perturbations in sphingolipid metabolism [60] and dysregulation of lipid metabolism have been associated with COPD development [59,61].
Supported by AllerGen, the Canadian Institutes of Health Research (CIHR), Genome Prairie, Genome Canada, an establishment grant from AHFMR, the Natural Science and Engineering Research Council of Canada (NSERC), the University of Alberta Hospital Foundation, and the Alberta Science and Research Authority (ASRA). B.H.R.'s research is supported by a Tier I Canada Research Chair in Evidence-based Emergency Medicine from the CIHR through the Government of Canada (Ottawa, Ontario, Canada). P.N. is supported by a Canada Research Chair in Airway Inflammometry through the Government of Canada (Ottawa, Ontario, Canada).
Disclosure of potential conflict of interest: D. J. Adamko has received research support from AllerGen NCE, Alberta Heritage Foundation for Medical Research, the Women and Children's Health Research Institute, and Grand Challenges Canada; has received travel support from AllerGen NCE; has received payment for lectures from Merck and Takeda; has planned patents with the University of Alberta; and is lead on a university-based start-up company seeking to develop metabolomics as a potential diagnostic test for asthma and related airways diseases. P. Nair has consultant arrangements with Sanofi, Teva, Roche, and Boehringer Ingelheim; has received research support from GlaxoSmithKline, AstraZeneca, and Novartis; has received payment for lectures from Merck and AstraZeneca; is listed on a patent for a sputum filtration device; and has provided consultancy to a university-based start-up company seeking to develop a sputum processing kit. I. Mayers has received research support from the Public Health Agency of Canada; is a board member for Amirall Canada, Boehringer Ingelheim, and Novartis; has consultant arrangements with Boehringer Ingelheim; is employed by the Canadian Drug Expert Committee; has provided expert testimony for the Worker's Compensation Committee; and has received payment for lectures from Amirall, Boehringer Ingelheim, and Novartis. R. T. Tsuyuki has received research support from AllerGen NCE, the Canadian Institutes of Health Research, Genome Prairie, Alberta Heritage Foundation for Medical Research, the Natural Sciences and Engineering Research Council, Merck, Sanofi, and AstraZeneca; has received travel support from AllerGen NCE; and is on the pharmacy advisory board for PharmaSmart. S. Regush has received research support from AllerGen NCE, the Canadian Institutes of Health Research, Genome Prairie, Alberta Heritage Foundation for Medical Research, and the Natural Sciences and Engineering Research Council. B. H. Rowe has received research support from the University of Alabama in Hunstville Foundation, Alberta Heritage Foundation for Medical Research/Alberta Innovates: Health Solutions, and Canadian Institutes of Health Research; is chair of the International Advisory Board for SREMI–Mt. Sinai Hospital; has consultant arrangements with AlphaCore; is employed by Alberta Health Services; has received payment for lectures from AstraZeneca and Pfizer; has planned patents with the University of Alberta; and is a researcher and contributor to a university-based start-up company seeking to develop a metabolomics diagnostic test for asthma and related airways diseases.